| Literature DB >> 15848049 |
Erdem Tüzün1, Matthew N Meriggioli, Julie Rowin, Huan Yang, Premkumar Christadoss.
Abstract
Steroid-dependent myasthenia gravis patients improved following treatment with etanercept (recombinant human TNF receptor:Fc) in a prospective pilot trial. While the plasma anti-acetylcholine receptor antibody levels remained unaffected, etanercept treatment increased plasma levels of C3, circulating immune complexes, IL-10 and IFN-gamma. There was a direct correlation between plasma IL-6, TNF-alpha and IFN-gamma levels and the post-treatment clinical scores of patients. Moreover, patients with lower pre-treatment plasma IL-6 and IFN-gamma levels attained better clinical improvement following etanercept treatment.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15848049 DOI： 10.1016/j.jaut.2005.01.013
Source DB: PubMed Journal: J Autoimmun ISSN： 0896-8411 Impact factor: 7.094